Evidence map›Paper›PMID 35284612›Full record

ReviewGynecologic oncology reports2022

Gynecologic oncology HPV vaccination practice patterns: Investigating practice barriers, knowledge gaps and opportunities for maximizing cervical cancer prevention.

Mali K Schneiter, Kimberly Levinson, Anne F Rositch, Rebecca L Stone, Amanda Nickles Fader, James Stuart Ferriss, Stephanie L Wethington, Anna L Beavis

Open access · goldAbstract readReview
In one paragraph

Review in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Barriers in the prevention and early detection of human papillomavirus in Latin America.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mali K SchneiterKelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 281, Baltimore, MD 21287-1281, USA.
Kimberly LevinsonKelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 281, Baltimore, MD 21287-1281, USA.
Anne F RositchDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205, USA.
Rebecca L StoneKelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 281, Baltimore, MD 21287-1281, USA.
Amanda Nickles FaderKelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 281, Baltimore, MD 21287-1281, USA.
James Stuart FerrissKelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 281, Baltimore, MD 21287-1281, USA.
Stephanie L WethingtonKelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 281, Baltimore, MD 21287-1281, USA.
Anna L BeavisKelly Gynecologic Oncology Service, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Phipps 281, Baltimore, MD 21287-1281, USA.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
NCI NIH HHS P50 CA098252
6 · The paper itself

Abstract

Objective: HPV vaccination is an important form of cancer prevention. Gynecologic oncologists have an opportunity to improve adult vaccination rates. We aimed to describe current HPV vaccination practices and barriers to vaccination reported by gynecologic oncologists. Methods: An online survey was developed, pilot tested and sent to U.S. members of the Society of Gynecologic Oncology. Results: Of the 226 respondents, most were female (73%), < 45 years old (64%) and practiced in urban (60%) and academic settings (69%). Ninety percent had recommended the HPV vaccine in the past year. Nearly half (47%) had facilitated vaccination by: administering the HPV vaccine in clinic (40%), stocking the vaccine (35%), or prescribing the vaccine (30%). Recommending the vaccine was associated with higher outpatient volume, practicing in the South vs. Northeast, and having higher levels of vaccine knowledge.Of the 90% who recommended the vaccine, 60% did not prescribe or know if they could prescribe the vaccine in their state. Prioritization of cancer treatment was the most commonly reported barrier to HPV vaccination (88%). Approximately half of providers reported other systems-level hinderances such as high cost of stocking the vaccine, clinic flow disruption, or uncertainty surrounding insurance coverage. Almost all recommenders offered the vaccine at HPV-related dysplasia (92%) or cancer (80%) visits, while only 24-50% offered it at non-HPV-related visits. Conclusions: These survey results identify patient, provider, and systems-level barriers that could be targeted to help increase adult HPV vaccination in gynecologic oncology clinics.

Indexed as

BarriersGynecologic oncologistsHPV-related Cancer preventionHPV vaccineHPV vaccine championSurvey

Identifiers

PMID35284612
PMCPMC8907676
OpenAlexW4214933088

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.